What’s going on with nitrosamines? Naiffer Romero from the USP walks us through frequently asked questions.

The search for an effective treatment for childhood brain cancers goes on, but a modified Herpes virus could represent a breakthrough.

Drug shortages are everywhere. We speak with Vimala Raghavendran at the US Pharmacopeia to get the full picture.

If used correctly, AI and ML expand our knowledge of biology and vastly improve the speed of success in the clinic.

We get the background on a new manufacturing platform for cell and gene therapy from Ori Biotech, tested by MD Anderson and Resilience’s CTMC.

We speak with the Alzheimer’s Society in the UK about their work. Find out more with The Medicine Maker

An expert from Samsung Biologics offers her perspective on the future of antibody drug conjugates.

Software development and CDMO experts share their key tips for choosing the right digital technologies and partnerships

NervGen President and CEO Mike Kelly discusses the potential of the company’s investigational drug NVG-291 for spinal cord injury.